In Vivo Imaging of Cerebral Circulation In Mouse Models of Polycythemia Vera

Blood ◽  
2010 ◽  
Vol 116 (21) ◽  
pp. 4091-4091
Author(s):  
Thom P. Santisakultarm ◽  
Nozomi Nishimura ◽  
Claire Paduano ◽  
Radek C. Skoda ◽  
William L. Olbricht ◽  
...  

Abstract Abstract 4091 Polycythemia vera (PV) is a myeloproliferative disease which is often associated with compromised cerebral microcirculation due to thrombotic and other rheological complications; this, in turn, may contribute to cognitive decline. Elevated blood viscosity may also lead to leukocyte adhesion, which further impacts cortical perfusion. An activating mutation, JAK2V617F, in the gene for JAK2, a cytoplasmic tyrosine kinase, is associated with PV in humans and transgenic mice carrying the same mutation have been developed. Our study aims to quantify the alterations in cerebral microcirculation in polycythemic mice and to determine the role of leukocyte adherence in disrupting blood flow, raising the possibility of a possible clinical therapeutic target for patients with PV. We used two models of PV: erythropoietin (EPO) injection (10-100 IU daily subcutaneous injections for 5 days) and a JAK2V617F transgenic mouse. Vascular topology and blood flow was imaged in anesthetized mice, through a craniotomy, using in vivo two-photon excited fluorescence microscopy. Texas-red dextran (0.05 mL of 2.5% w/v) and rhodamine 6G (0.05 mL of 0.1% w/v) were intravenously injected to label blood plasma and leukocytes, respectively. RBC flow speed was measured in arterioles, capillaries, and venules. Brain capillaries were classified as flowing or stalled by evaluating the motion of RBCs within individual vessels. We found a significant decrease in average capillary flow speed in EPO-injected mice, with an average hematocrit (Hct) of 60% (0.70±0.533 mm/s. 10 mice, 105 vessels, p<0.01) and JAK2V617F transgenic mice with Hct of 67% (0.55±0.362 mm/s. 3 mice, 47 vessels, p<0.01) compared to wild type controls with Hct of 48% (1.24±0.986 mm/s. 9 mice, 92 vessels), but not in surface arterioles or venules. In EPO-injected mice, 20% of the capillaries were stalled (12 mice, 6594 vessels, p<0.01), compared to only 3% in control mice (5 mice, 2431 vessels). In JAK2V617F transgenic mice, we found 25% of the capillaries were stalled (4 mice, 4574 vessels, p<0.01). Further, we observed firm leukocyte adherence in a large fraction of the stalled capillaries in the EPO-injected and JAK2V617F transgenic mice (see Figure). Our findings suggest that high Hct creates flow conditions which lead to leukocyte adherence, and may result in leukocyte activation. This work suggests that targeting leukocyte adherence and reducing the hematocrit may be clinically important in patients with PV and other diseases with high blood viscosity to ameliorate abnormal cerebral blood flow. Disclosures: No relevant conflicts of interest to declare.

Author(s):  
Enrico D.F. Motti ◽  
Hans-Georg Imhof ◽  
Gazi M. Yasargil

Physiologists have devoted most attention in the cerebrovascular tree to the arterial side of the circulation which has been subdivided in three levels: 1) major brain arteries which keep microcirculation constant despite changes in perfusion pressure; 2) pial arteries supposed to be effectors regulating microcirculation; 3) intracerebral arteries supposed to be deprived of active cerebral blood flow regulating devices.The morphological search for microvascular effectors in the cerebrovascular bed has been elusive. The opaque substance of the brain confines in vivo investigation to the superficial pial arteries. Most morphologists had to limit their observation to the random occurrence of a favorable site in the practically two-dimensional thickness of diaphanized histological sections. It is then not surprising most investigators of the cerebral microcirculation refer to an homogeneous network of microvessels interposed between arterioles and venules.We have taken advantage of the excellent depth of focus afforded by the scanning electron microscope (SEM) to investigate corrosion casts obtained injecting a range of experimental animals with a modified Batson's acrylic mixture.


1977 ◽  
Vol 38 (04) ◽  
pp. 0823-0830 ◽  
Author(s):  
Mayrovttz N. Harvey ◽  
Wiedeman P. Mary ◽  
Ronald F. Tuma

SummaryIn vivo studies of the microcirculation of an untraumatized and unanesthetized animal preparation has shown that leukocyte adherence to vascular endothelium is an extremely rare occurrence. Induction of leukocyte adherence can be produced in a variety of ways including direct trauma to the vessels, remote tissue injury via laser irradiation, and denuding the epithelium overlying the observed vessels. The role of blood flow and local hemodynamics on the leukocyte adherence process is quite complex and still not fully understood. From the results reported it may be concluded that blood flow stasis will not produce leukocyte adherence but will augment pre-existing adherence. Studies using 2 quantitative measures of adherence, leukocyte flux and leukocyte velocity have shown these parameters to be affected differently by local hemodynamics. Initial adherence appears to be critically dependent on the magnitude of the blood shear stress at the vessel wall as evidenced by the lack of observable leukocyte flux above some threshold value. Subsequent behavior of the leukocytes as characterized by their average rolling velocity shows no apparent relationship to shear stress but, for low velocities, may be related to the linear blood velocity.


2016 ◽  
Vol 36 (suppl_1) ◽  
Author(s):  
P Mason McClatchey

Introduction: Impaired tissue oxygenation is observed in many disease states including congestive heart failure, diabetes, cancer and aging. Decreased tissue perfusion and heterogeneous distribution of blood flow in the microvasculature contributes to this pathology. The physiological mechanisms regulating homogeneity/heterogeneity of microvascular perfusion are presently unknown. We hypothesized that microfluidic properties of the glycocalyx would promote perfusion homogeneity. Methods: To test our hypothesis, we used established empirical formulations for modelling blood viscosity in vivo (blood vessels) and in vitro (glass tubes). We first assess distribution of blood flow in idealized arteriolar networks. We next simulated distribution of blood flow at an idealized capillary bifurcation. Finally, we simulated velocity profiles and pressure gradients within the vessel lumen with varying glycocalyx properties using a computational fluid dynamics approach. Results: We found that transit time heterogeneity (as assessed by STD to mean ratio) was increased approximately 9x (6.9x-10.6x) using in vitro formulations of blood viscosity relative to in vivo formulations. This effect was mathematically accounted for by increased effective blood viscosity in smaller arterioles. We also found that distribution of blood flow at an idealized microvascular bifurcation was more symmetric using the in vivo formulation than the in vitro formulation (approximately 2x greater disparity between flow in downstream vessels). This effect was mathematically accounted for by an increased hematocrit dependence of blood viscosity. Both the diameter- and hematocrit-based changes in blood viscosity were entirely predictable from fluid dynamics simulations incorporating a space-filling, semi-permeable glycocalyx layer. Summary: Our simulations indicate that the mechanical properties of the endothelial glycocalyx promote homogeneous microvascular perfusion. Conclusions: The literature provides evidence of both glycocalyx degradation and impaired tissue perfusion in the same disease states. Preservation or restoration of normal glycocalyx properties may be a viable strategy for improving tissue perfusion in a wide variety of diseases.


2012 ◽  
Vol 32 (7) ◽  
pp. 1167-1176 ◽  
Author(s):  
Yoshiaki Itoh ◽  
Norihiro Suzuki

While it has been widely confirmed that cerebral blood flow is closely coupled with brain metabolism, it remains a matter of controversy whether capillary flow is directly controlled to meet the energy demands of the parenchyma. Since the capillary is known to lack smooth muscle cells, it has generally been considered that capillary flow is not regulated in situ. However, we now have increasing data supporting the physiological control of capillary flow. The observation of heterogeneity in the microcirculation in vivo has suggested that intravascular factors may be involved in the flow control, including non-Newtonian rheology, red blood cell flow, leukocyte adhesion, release of vasoactive mediators, and expression of glycoproteins on the endothelial cells. Astrocytes, a key mediator of the neurovascular unit, and intrinsic innervation may also regulate capillary flow. In addition, recent findings on pericyte contractility have attracted the attention of many researchers. Finally, based on these findings, we present a new model of flow control, the proximal integration model, in which localized neural activity is detected at nearby capillaries and the vasodilation signal is transmitted proximally along the vessel. Signals are then integrated at the precapillary arterioles and other arterioles further upstream and regulate the capillary flow.


Blood ◽  
2015 ◽  
Vol 126 (23) ◽  
pp. 2825-2825
Author(s):  
Titiksha Basu ◽  
Albert Gruender ◽  
Christine Dierks ◽  
Heike L Pahl

Abstract Even after the discovery of JAK2V617F in majority of Polycythemia Vera (PV) patients and the generation of JAK2 inhibitors, the treatment of PV remains to be improved. An increased understanding of aberrant signaling in PV cells may yield novel drug targets for this patient population. The formation of erythroid colonies in the absence of exogenous erythropoietin (Epo), so called Epo-independent erythroid colonies (EECs), is a pathognomonic hallmark of PV. Over 20 years ago, Axelrad and colleagues proposed that EEC formation is not due to Epo-independence. Rather, they postulated that PV cells are hypersensitive to Insulin Growth Factor-1 (IGF-1). Subsequently, increased IGF-1 receptor (IGF-1R) phosphorylation was demonstrated in PV MNCs. In addition, serum concentrations of IGF-1 binding protein (IGF-1BP) are significantly elevated in PV patients. It has been shown that IGF-1 cooperates with JAK2V617F to increase JAK/STAT signaling, elevating constitutive phosphorylation of STAT factors and thereby augmenting aberrant proliferation. We therefore hypothesized that inhibition of IGF-1 signaling would ameliorate the PV phenotype, even in the presence of JAK2V617F. The dual IGF-1R and insulin receptor (IR) kinase inhibitor linsitinib (formerly called OSI-906) was used to investigate the contribution of the IGF-1 pathway to PV pathophysiology. In methylcellulose colony assays, linsitinib significantly reduced the EEC formation from PV MNCs. In contrast, in the presence of EPO, colony formation from either PV or healthy control MNCs was not affected. These data suggest that linsitinib specifically inhibits growth of the PV clone. Linsitinib likewise significantly reduced the cytokine independent proliferation of Ba/F3 cells expressing JAK2V617F but did not affect proliferation of Ba/F3 cells expressing either JAKWT or JAK2V617F in the presence of cytokine (mIL3). These data again argue that IGF-1 signalling is required for aberrant, cytokine independent growth. In addition to reducing proliferation, Linsitinib also induced apoptosis in IL3-independent JAK2V617F transduced Ba/F3 cells. Using the JAK2V617F bone marrow transplant (BMT) model, we investigated the effect of linsitinib on the PV phenotype in vivo. Linsitinib treatment significantly reduced the elevated RBC count, hematocrit and hemoglobin in this PV mouse model. In addition, the white blood cell count was decreased. The data presented here provide a pre-clinical rationale for expanding the investigation of linsitinib as well as similar IGF-1 pathway inhibitors for the treatment of PV. The effect of combining JAK2 and IGF-1 inhibition may prove especially promising in this patient population and is currently being investigated. Disclosures No relevant conflicts of interest to declare.


Blood ◽  
2011 ◽  
Vol 118 (21) ◽  
pp. 2099-2099
Author(s):  
Xiuling Xu ◽  
Jeff S. Friedman

Abstract Abstract 2099 Redox equilibrium is an important determinant of malaria pathology and host defensive response to malaria parasites. Many anti-malarial drugs are reported to increase oxidative stress in red cells (RBC). Drug-induced hemolysis, particularly in G6PD deficient individuals, limits the utility of approved 8-aminoquinolones such as primaquine. The search for derivatives of primaquine that maintain efficacy without RBC toxicity is hampered by lack of a predictive assay for hemolytic potential. In order to monitor in vivo RBC redox changes in response to anti-malaria drugs, we have established a transgenic mouse line specifically expressing a redox sensitive GFP (roGFP2) in RBC1. RoGFP2 is an engineered EGFP with 2 cysteines introduced at amino acid positions 147 and 2042. When oxidized, the 2 cysteines form a disulfide bond, resulting in a protein conformational change that alters the spectral properties of the GFP. By following the ratio of fluorescence emission at 520nm after excitation at 405 vs 488nm, the intracellular redox potential in live cells can be determined. Here we apply this novel mouse model to follow in vivo RBC redox status upon exposure of transgenic mice to a series of 8-AQÕs and control compounds including known hemolytic agents such as dapsone. Unlike in vitro studies, these whole animal experiments incorporate metabolic transformation of inert parent compounds, pharmacokinetics and a time-course that closely models clinical hemolytic reactions in susceptible individuals exposed to the same drugs. roGFP2 transgenic mice (N=4 per group) were given test compounds (primaquine, chloroquine, dapsone and 1161B*) by gavage 2X/day at a total dose of 50mg/Kg over a period of 5 days. Peripheral RBC were analyzed using a LSRII FACS (BD) to determine the 405/488 ratio, and thus follow the redox status as shown in the figure below. Chloroquine treatment did not cause detectable change in roGFP2 signal, in agreement with previous data that chloroquine does not induce ROS production or hematotoxicity. Treatment with 1161B induced a steady increase in roGFP2 ratio that was first evident at 3 days of treatment, while primaquine treatment has little effect. Dapsone serves as a positive control in this assay, as a known hemolytic agent requiring metabolic activation to produce a redox cycling metabolite.3 Treatment with dapsone produced a time dependent shift to a more oxidized state of roGFP2 that was first evident after 2 days of drug administration. Consistent with these results, CBCÕs obtained one week after start of treatment showed moderate and mild hemolysis in those mice receiving dapsone and 1161B, respectively. In summary, roGFP2 transgenic mice provide a promising platform for assessment of hemolytic potential of drugs—here demonstrated using dapsone and 8-aminoquinolones. While the mice used in this study were GFP transgenic on a wild-type background, studies are in progress to assess whether strains with specific RBC defects (such as G6PD hypomorphs, PRDX2 KO andSOD1 KO) are more sensitive to hemolytic insults. Preliminary studies indicate that PRDX2 and SOD1 KO mice are more sensitive to primaquine, but not chloroquine, according to the roGFP2 ratio changes. G6PD deficient animals may prove particularly useful for discriminating compounds such as primaquine that are safe for normal individuals, but cause hemolysis in the context of enzyme deficiency. *1161B is the B enantiomer of an 8-aminoquinolone derivative with better efficacy and reduced hematoxicity4,5 in mice, when compared to the racemic mixture of the same compound. Disclosures: No relevant conflicts of interest to declare.


2019 ◽  
Author(s):  
Weiye Song ◽  
Libo Zhou ◽  
Ji Yi

AbstractOblique scanning laser ophthalmoscopy (oSLO) is a recently developed technique to provide three-dimensional volumetric fluorescence imaging in retina over a large field of view, without the need for depth sectioning. Here in the paper, we present high-speed volumetric fluorescein angiography (vFA) in mouse retina in vivo by oSLO. By simply using a low-cost industrial CMOS camera, we improved the imaging speed by ~10 times comparing to our previous results, achieving vFA at 2 volumes per second. Enabled by high-speed vFA, we visualized hemodynamics at single capillary level in 3D and provided methods to quantify capillary hematocrit, absolute capillary blood flow speed, and detection of capillary flow stagnancy and stalling. The quantitative metrics for capillary hemodynamics at 3D retinal capillary network can offer valuable insight in vision science and retinal pathologies.


Author(s):  
Hiroko Kadowaki ◽  
Takuya Kishimoto ◽  
Takeshi Tokunaga ◽  
Koji Mori ◽  
Takashi Saito

Abstract Although blood viscosity has attracted much attention for its effect on hemodynamic parameters related to atherosclerosis, quantitative method for evaluating blood viscosity in vivo is not currently established. The purpose of this study was to verify the feasibility of blood viscosity estimation by a two-dimensional ultrasonic-measurement-integrated (2D-UMI) analysis system that computes an intravascular blood flow field by feeding back an ultrasonic measurement data to a numerical simulation. A method to estimate blood viscosity was proposed by reproducing the flow field of an analysis object in the feedback domain of ultrasonic Doppler velocity in a 2D-UMI blood flow analysis system, and evaluating the variation of the Doppler velocity caused by the analysis viscosity in the nonfeedback domain at the downstream side. In a numerical experiment, a viscosity estimation was performed for numerical solutions of sinusoidal oscillating flows analyzed as a blood flow model in a human common carotid artery at four different types of blood viscosities. The estimation viscosities were made to correspond to those of all analysis objects by giving proper conditions on the feedback gain and feedback domain to optimize the accuracy of the 2D-UMI blood flow analysis. In conclusion, the feasibility of blood viscosity estimation by 2D-UMI analysis was established. Simultaneous measurement of the in vivo blood viscosity and flow field can be easily performed in many clinical cases by its widespread use at clinical sites, thereby clarifying the relationship between hemodynamics and vascular pathology for various blood flow fields.


Blood ◽  
2021 ◽  
Vol 138 (Supplement 1) ◽  
pp. 4501-4501
Author(s):  
Syed Mehdi ◽  
Ying-Zhi Xu ◽  
Leonard Shultz ◽  
Samantha L. Kendrick ◽  
Donghoon Yoon

Abstract Introduction DLBCL is a commonly diagnosed, aggressive non-Hodgkin's lymphoma with ~40% of patients experiencing refractory or relapsed disease. Development of alternative therapies that target molecular features defining these unresponsive tumors is an active area of research to significantly advance the field and improve these patient's clinical management. However, few DLBCL animal models exist to test the efficacy of newly developed treatments, and are restricted to transgenic or xenograft mice that often fail to recapitulate the heterogeneous sub-classifications of this complex disease. While transgenic mice allow for spontaneous tumor formation, these models rely on inducing expression of specific oncogenes that drive a select group of DLBCL. The xenograft model offers several advantages, such as reproducing late-stage disease and shortening the model development time, but consist of implanting the tumor cells in a localized region or subcutaneously into immune-deficient mice. Despite some benefits of the transplant approach, these models are limited by their engraftment reproducibility and interactions with host micro-environments. Here, we explored the utility of humanizing Nod-Scid-IL2Rg null (NSG) mouse strains with factors associated with enhancing myeloid and lymphoma cell growth to establish a pipeline for rapid, reliable generation of in vivo DLBCL models. Methods We transduced the well-established human DLBCL cells, U2932, with the luciferase (Luc)-EGFP gene. The Luc-expressing (U2932-Luc) tumor cells were sorted for GFP positivity (GFP +) and expanded. The U2932-Luc cells (1 x 10 6/100µl PBS) were injected IV via tail vein into 8~12-week-old mice of various humanized NSG strains (representing equal numbers of each sex). NSG mice were humanized by transgenic expression of human cytokines (either human IL6 alone or IL6 plus SCF, GM-CSF, and IL-3) with the CMV promoter. Each experiment included of U2932-Luc cell transplanted group and control groups. We assessed U2932-Luc cell engraftment and growth by weekly in vivo imaging (IVIS 200 Imager, Perkin Elmer). To evaluate the organ specific engraftment/progression, we confirmed engraftment by bioluminescence imaging at the 2 nd week, then euthanized one mouse per week. At 15 minutes before euthansia, luciferin was injected via intraperitoneal injection. Following euthanasia, the organs were excised and underwent ex vivo IVIS imaging. The spleen, lungs, and liver were then fixed with 10% formalin and embedded in paraffin. Sections were stained with hematoxylin and eosin, and an anti-CD20 antibody to evaluate the tumor morphology using a Zeiss AXIO Imager M2 microscope (Zeiss, Nashville, TN). All other mice were monitored for survival and the median survival between the IL6 and IL6/SGM3 mice were compared using the Log-rank test. Results Similar to previously reported DLBCL humanized strain (MISTRG) (Hashwah, 2019), we used the IL6/SGM3 expressing strain. However, our studies also included the IL6 only humanized strain. We found that both the IL6 and IL6/SGM3 strains were highly permissive to DLBCL growth. The IL-6 strain exhibited a heightened growth of U2932 cells relative to the IL-6/SGM3 mice. As shown in Figure 1, the IL6 mice survived longer than IL6/SGM3 mice. Significant difference between the median survival of IL6 and IL6/SGM3 mice i.e. 48 days vs 42 days was observed (p &lt; 0.0482). The organ specific evaluation demonstrated that U2932-Luc cells were initially engrafted and grew in the lung, liver, and spleen. Subsequently, U2932 cells were found in the skeleton, ovary, and brain. Of note, we detected significantly enlargements of the kidney, spleen, and ovary at the terminal stage. Conclusions Our humanized mouse model approach of using U2932 human DLBCL cells transduced with the Luc gene in the NSG-IL6 and NSG-IL6/SGM3 mice reproduced the clinical features of an aggressive DLBCL that paralleled the original patient. This model will provide a new tool to enable expansion of patient samples while overcoming the current limitations of DLBCL xenografts and transgenic mice. The ability to maintain growth of patient-derived samples within clinically relevant locations has great potential to more accurately test patient-specific, personalized treatment strategies. Figure 1 Figure 1. Disclosures No relevant conflicts of interest to declare.


2020 ◽  
Vol 11 (5) ◽  
pp. 2738 ◽  
Author(s):  
Hongji Liu ◽  
Xinlin Chen ◽  
Xiangquan Deng ◽  
Ziwei Zhuang ◽  
Shen Tong ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document